Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announce that it has successfully completed its doseranging toxicology studies in rats and dogs, for its lead drug candidate MB204. These studies will assist in determining the doses for the INDenabling 4week GLP toxicology studies.

MB204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration.